After hundreds of hours of test drives, research and evaluation by independent jurors, the Genesis G70, Hyundai Kona/Kona EV and Ram 1500 were revealed as the winners of the 2019 North American Car, Utility and Truck of the Year (NACTOY) awards presented today at the North American International Auto Show in Detroit.
Chosen by a panel of 54 respected jurors from print, online, radio and broadcast media across the U.S. and Canada – rather than a single publication or media outlet – the awards are among the most prestigious and unique in the industry.
To view the multimedia release go to:
https://www.multivu.com/players/English/8467551-2019-north-american-car-utility-truck-awards/
Despite a dramatic increase in participation over the last decade, a new household survey commissioned by the Afterschool Alliance finds a significant gap between the demand and supply of afterschool programs. The 2014 edition of America After 3PM, which includes responses from 30,000 U.S. families, finds that for every child enrolled in an afterschool program, there are two more who are not and whose parents would enroll their child, if a program were available.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7335451-afterschool-alliance-survey-finds-unmet-demand-for-afterschool-programs/
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
UNIVERSO, is set to premiere season three of the hit celeb-reality “The Riveras” starring Chiquis, Jacqie, and Mike, Jenicka and Johnny, Sunday, March 11th at 10pm /9C. The 14-episode season offers viewers a lens into the lives of the children of the late Regional Mexican music legend, Jenni Rivera as they take on life’s challenges by supporting each other. The top rated show is the only English-language reality about a Hispanic family in the U.S. and its relatability has been the key to the show’s success. “The Riveras” reflects the diversity in this country, and the fastest growing population. To get a first look of the new season, open this YouTube link https://youtu.be/bLBoX1nyadk. To download press materials, visit EPK site www.image.net/TheRiveras.
To view the multimedia release go to:
https://www.multivu.com/players/English/8265551-nbc-universo-the-riveras/
Super hero fans around the country had a chance to put their own Spidey senses to the test by creating original DIY suits inspired by Sony Pictures’ new movie, “Spider-Man: Homecoming,” in theaters today, Friday, July 7 in the U.S. After narrowing the entries down to 10 semi-finalists and then five finalists, one especially crafty entrant won a trip to the world premiere screening of “Spider-Man: Homecoming” on Wednesday, June 28, 2017.
Tiffany Mink (@tiffmink) turned a red dress found at her local Goodwill store into a full-fledged, head-to-toe super hero outfit. Her video showing how she created the suit, along with the submissions from the other finalists, can be viewed at spidermandiy.com. Entrants were encouraged to put their super hero love to work alongside their senses of style, and to act as community heroes by sourcing materials for their suits from Goodwill, where the sale of donated goods creates job preparation, skills training, education assistance and support services for people who face challenges to finding employment. Tiff’s purchases equates to 40 minutes of job search training for a Goodwill participant.
To view the multimedia release go to:
https://www.multivu.com/players/English/8133751-goodwill-diy-spider-man-costume-contest/
In the age of smartphones, smart pads, and big data, John Sculley is the quintessential smart entrepreneur. John Sculley is one of America's best-known business leaders, with one foot in the storied history of Apple technology and the other planted firmly in 21st century innovations that change the way the world does business. Few entrepreneurs have been as successful across so many fields as Sculley. John Sculley, current investor and builder of dozens of businesses in the U.S. and abroad, today introduced a new book and multimedia business learning series.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7334351-john-sculley-new-book-multimedia-business-series-build-billion-dollar-businsses/
KitchenAid has exciting news for Stand Mixer lovers everywhere. The power, iconic design, color choices and endless possibilities synonymous with this culinary workhorse will soon be available in a size ideally suited for limited counter space and “smaller batch” lifestyles.
The new Artisan® Mini Stand Mixer is scheduled to initially launch in the U.S. this summer, with a global launch slated for later in the year. Offering the same power and performance as the brand’s Classic™ Stand Mixer, the Mini Artisan mixer features a 3.5-quart capacity and is 20% smaller and 25% lighter. It joins a collection that includes 4.5-, 5-, 6- 7-, and 8-quart models, and represents the first downsizing of the Stand Mixer since 1962. Manufacturer’s suggested retail price is $399.99.
To view the multimedia release go to:
http://www.multivu.com/players/English/7766751-kitchenaid-artisan-mini-stand-mixer/
Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses are the only lenses in the United States that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the Tecnis Symfony Toric IOL.
Cataracts are a common condition, with almost 4 million cataract surgeries performed each year, and that number is expected to increase.1 By age 80, more than half of all Americans either have a cataract or have had cataract surgery.2 However, cataracts do not just impact seniors. In 2016 it is estimated that nearly one in four cataract surgeries will be performed on people younger than 65.1 Many people who have cataracts experience other problems with their vision, such as presbyopia and astigmatism, which the Symfony lenses also address. Presbyopia, which affects most people over age 40, means people have lost the ability to focus on objects up close and often require glasses to perform near visual tasks. Astigmatism is when the cornea is misshapen, which causes blurry or distorted vision.
To view the multimedia release go to:
http://www.multivu.com/players/English/7870151-abbott-intraocular-lenses/
Rowenta, maker of the revolutionary new air purifier the Intense Pure Air, is collaborating with renowned Environmental Toxicologist Dr. Noreen Khan-Mayberry (aka “The Tox Doc”), to help allergy sufferers better manage their symptoms. An estimated 50 million Americans are allergic to dust, dander, mold and mites, which can cause trouble breathing, excessive sneezing, eye irritation and coughing, amongst other ailments.
Seasonal allergies affect approximately 30% of U.S. residents and are worsening due to climate change, which is not only causing an increase in pollen levels, but also extending the length of pollen season. As such, allergy sufferers and people with asthma and other respiratory issues are at an even greater risk for heightened symptoms both indoors and outdoors.
To view the multimedia release go to:
http://www.multivu.com/players/English/7779051-rowenta-intense-allergen-air-purifier/
Das Kompaktwagen-Segment ist ebenso beliebt wie wettbewerbsintensiv – insbesondere in Deutschland. Jeder vierte Autokäufer entscheidet sich für diese Klasse. Auch wenn VW mit dem Dauerbrenner Golf mit einem Marktanteil von über 30 Prozent alle Wettbewerber dominiert – wer als Großserien-Hersteller mitmischen will, muss sich in dieser Klasse vom verbleibendem Kuchen ein möglichst großes Stück erobern. Diese Aufgabe hat bei Peugeot die am 21. September auf den Markt kommende neue Generation des 308, der seit seinem Erscheinen in 2001 immerhin insgesamt 4,2 Millionen Käufer fand. Und dies dringend – denn trotz ordentlicher Verkäufe des neuen 208 befindet sich Peugeot bei uns nach wie vor im Rückwärtsgang. Bis einschließlich August beträgt das Zulassungsminus satte 28,9 Prozent gegenüber dem Vorjahreszeitraum und das bei einem durchschnittlichen Branchen-Gesamtrückgang von 6,6 Prozent. Mit einer Länge von 4,25 Metern ist der neue 308 die kompakteste Limousine ihres Segments. Auch der Karosserieüberhang fällt vorn wie hinten überraschend kurz aus, was ihm eine dynamische Optik verleiht, ohne die Platzverhältnisse im Innenraum einzuschränken. Dank des auf 2,52 Meter vergrößerten Radstands profitieren Insassen im Innenraum von mehr Bewegungsfreiheit. Das Kofferraumvolumen von 470 Litern (VDA-Norm: 420 Liter), von dem 35 Liter unter dem Bodenteppich versteckt sind, stellt nach Angaben von Peugeot einen Rekordwert im Segment dar. Darüber hinaus gibt es im Innenraum zahlreiche weitere Ablagemöglichkeiten wie das zwölf Liter große Handschuhfach oder die großen Seitentaschen an den Vordertüren.
Bu videoda birçok akıllı maymunlar ile yapılan testleri görebilirsiniz. Bazıları işaret dilinde konuşuyor, bazıları bilgisayar ile anlaşıyor, bazıları lexigram kullanıyor, birçoğu söylenenleri anlıyor, kısacası iyi seyirler.
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
